Skip to main content

MOLECULAS BASADAS EN DONEPECILO CON CAPACIDAD PARA INTERACCIONAR CON LOS SISTEMAS MONOAMINERGICO, COLINERGICO, Y SECUESTRAR METALES PESADOS, PARA LA ENFERMEDAD DE ALZHEIMER

SAF2012-33304

•
Funding agency name Ministerio de Economía y Competitividad
Funding agency acronym MINECO
Program Programa Nacional de Proyectos de Investigación Fundamental
Subprogram Subprograma de Proyectos de Investigación Fundamental no Orientada
Call Proyectos I+D
Call year 2012
State Plan 2008-2011 Plan Nacional de Investigación Científica, Desarrollo e Innovación Tecnológica
Management unit Secretaría de Estado de Investigación, Desarrollo e Innovación
Beneficiary centre AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

5-Amino-6,7,8,9-Tetrahydrobenzo[b][1,8]Naphthyridin-2(1H)-One: The first Example of a new Family of HuperTacrines for Alzheimer's Disease Therapy

  • Balmori, Alba
  • Chioua, Mourad
  • Bellacasa, R. P. de la
  • Estrada-Tejedor, R.
  • Ismaili, Lhassane
  • Marco-Contelles, José
  • Borrell, J. I.
In this communication we have described the synthesis of 2-amino-6-oxo-1,6-dihydropyridine-3-carbonitrile (4), and the preparation of 5-amino-6,7,8,9-tetrahydrobenzo[b][1,8]naphthyridin-2(1H)-one (3 a), a non-hepatotoxic, antioxidant agent, showing moderate, but selective human acetylcholinesterase inhibition., JMC thanks MINECO (SAF2012-33304), and Universidad Camilo José Cela (MULTIMOL 2013–20) for support, Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Neuroinflammation Signaling Modulated by ASS234, a Multitarget Small Molecule for Alzheimer's Disease Therapy

  • Pino, Javier del
  • Marco-Contelles, José
  • López-Muñoz, Francisco
  • Romero Jódar, Alejandro
  • Ramos, Eva
There is clear evidence that neuroinflammation plays a crucial role in the pathogenesis of Alzheimer's disease. Consequently, modulating the inflammatory environment in brain has become a powerful and attractive strategy to deal with Alzheimer's disease physiopathology. In spite of the neuroprotective capacity shown by ASS234, a multitarget propargylamine targeted for Alzheimer's disease, its regulation of inflammation in the brain still remains unexplored. Therefore, we aimed to characterize possible anti-inflammatory effects of ASS234, counteracting induced inflammatory effects in RAW 264.7 cells and evaluating seven neuroinflammation related genes expression profiling (IL-6, IL-10, IL1β, NF-κB, TNF-α, TNFR1, and TGF-β), after ASS234 (5 μM) treatment in SH-SY5Y cells. The analysis of the obtained fold changes lead us to conclude that ASS234 may play an important role facing the neuroinflammatory environment in Alzheimer's disease pathology., J.M.-C. is indebted to MINECO for Grants SAF2012-33304 and SAF2015-65586-R. The authors thank Camilo José Cela University [Project 2015-21 (HISCHEMAO)] for its continued support., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

The proof-of-concept of ASS234: Peripherally administered ASS234 enters the central nervous system and reduces pathology in a male mouse model of Alzheimer disease

  • Serrano, Mari Paz
  • Herrero-Labrador, Raquel
  • Futch, Hunter S.
  • Serrano, Julia
  • Romero, Alejandro
  • Fernández Fernández, Ana Patricia
  • Samadi, Abdelouahid
  • Unzeta, Mercedes
  • Marco-Contelles, José
  • Martínez-Murillo, Ricardo
The heterogeneity of Alzheimer disease requires the development of multitarget drugs for treating the symptoms of the disease and its progression. Both cholinergic and monoamine oxidase dysfunctions are involved in the pathological process. Thus, we hypothesized that the development of therapies focused on these targets might be effective. We have developed and assessed a new product, coded ASS234, a multipotent acetyl and butyrylcholinesterase/monoamine oxidase A-B inhibitor with a potent inhibitory effect on amyloid-β aggregation as well as antioxidant and antiapoptotic properties. But there is a need to reliably correlate in vitro and in vivo drug release data., The study received research support from the MINECO (Government of Spain grant SAF2015-65586 awarded to R. Martínez-Murillo and J. Marco-Contelles and grant SAF2012-33304 awarded to J. Marco-Contelles). The authors thank Universidad Camilo José Cela for support (grant 2014-35)., Peer reviewed
Docta Complutense
Publication Artículo científico (JournalArticle)

The proof-of-concept of ASS234: Peripherally administered ASS234 enters the central nervous system and reduces pathology in a male mouse model of Alzheimer disease

  • Serrano Regal, María Paz
  • Herrero Labrador, Raquel
  • Futch, Hunter S.
  • Serrano, Julia
  • Romero Martínez, Manuel Alejandro
  • Fernandez, Ana Patricia
  • Samadi, Abdelouahid
  • Unzeta, Mercedes
  • Marco Contelles, José Luis
  • Martínez Murillo, Ricardo
Background: The heterogeneity of Alzheimer disease requires the development of multitarget drugs for treating the symptoms of the disease and its progression. Both cholinergic and monoamine oxidase dysfunctions are involved in the pathological process. Thus, we hypothesized that the development of therapies focused on these targets might be effective. We have developed and assessed a new product, coded ASS234, a multipotent acetyl and butyrylcholinesterase/monoamine oxidase A–B inhibitor with a potent inhibitory effect on amyloid-β aggregation as well as antioxidant and antiapoptotic properties. But there is a need to reliably correlate in vitro and in vivo drug release data. Methods: We examined the effect of ASS234 on cognition in healthy adult C57BL/6J mice in a model of scopolamine-induced cognitive impairment that often accompanies normal and pathological aging. Also, in a characterized transgenic APPswe/PS1ΔE9 mouse model of Alzheimer disease, we examined the effects of short-term ASS234 treatment on plaque deposition and gliosis using immunohistochemistry. Toxicology of ASS234 was assessed using a quantitative high-throughput in vitro cytotoxicity screening assay following the MTT assay method in HepG2 liver cells. Results: In vivo, ASS234 significantly decreased scopolamine-induced learning deficits in C57BL/6J mice. Also, reduction of amyloid plaque burden and gliosis in the cortex and hippocampus was assessed. In vitro, ASS234 exhibited lesser toxicity than donepezil and tacrine. Limitations: The study was conducted in male mice only. Although the Alzheimer disease model does not recapitulate all features of the human disease, it exhibits progressive monoaminergic neurodegeneration. Conclusion: ASS234 is a promising alternative drug of choice to treat the cognitive decline and neurodegeneration underlying Alzheimer disease.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease, design, synthesis, biochemical evaluation, ADMET, molecular modeling, and QSAR analysis of novel donepezil-pyridyl hybrids

  • Bautista-Aguilera, Oscar M..
  • Esteban, Gerard|||0000-0002-9383-2150
  • Chioua, Mourad
  • Nikolic, Katarina
  • Agbaba, Danica
  • Moraleda, Ignacio
  • Iriepa, Isabel
  • Soriano, Elena
  • Samadi, Abdelouahid
  • Unzeta López, Mercedes|||0000-0002-7113-3383
  • Marco-Contelles, José
The design, synthesis, and biochemical evaluation of donepezil-pyridyl hybrids (DPHs) as multipotent cholinesterase (ChE) and monoamine oxidase (MAO) inhibitors for the potential treatment of Alzheimer's disease (AD) is reported. The 3D-quantitative structure-activity relationship study was used to define 3D-pharmacophores for inhibition of MAO A/B, acetylcholinesterase (AChE), and butyrylcholinesterase (BuChE) enzymes and to design DPHs as novel multi-target drug candidates with potential impact in the therapy of AD. DPH14 (Electrophorus electricus AChE [EeAChE]: half maximal inhibitory concentration [IC] =1.1±0.3 nM; equine butyrylcholinesterase [eqBuChE]: IC.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Multi-Target Directed Donepezil-Like Ligands for Alzheimer's Disease

  • Unzeta López, Mercedes|||0000-0002-7113-3383
  • Esteban, Gerard|||0000-0002-9383-2150
  • Bolea Tomás, Irene|||0000-0001-9591-980X
  • Fogel, Wieslawa A.
  • Ramsay, Rona R.
  • Youdim, Moussa B. H.
  • Tipton, Keith F.
  • Marco-Contelles, José
HIGHLIGHTS Alzheimer's disease (AD), the most common form of adult onset dementia, is an age-related neurodegenerative disorder characterized by progressive memory loss, decline in language skills, and other cognitive impairments. Although its etiology is not completely known, several factors including deficits of acetylcholine, β-amyloid deposits, τ-protein phosphorylation, oxidative stress, and neuroinflammation are considered to play significant roles in the pathophysiology of this disease. For a long time, AD patients have been treated with acetylcholinesterase inhibitors such as donepezil (Aricept®) but with limited therapeutic success. This might be due to the complex multifactorial nature of AD, a fact that has prompted the design of new Multi-Target-Directed Ligands (MTDL) based on the "one molecule, multiple targets" paradigm. Thus, in this context, different series of novel multifunctional molecules with antioxidant, anti-amyloid, anti-inflammatory, and metal-chelating properties able to interact with multiple enzymes of therapeutic interest in AD pathology including acetylcholinesterase, butyrylcholinesterase, and monoamine oxidases A and B have been designed and assessed biologically. This review describes the multiple targets, the design rationale and an in-house MTDL library, bearing the N -benzylpiperidine motif present in donepezil, linked to different heterocyclic ring systems (indole, pyridine, or 8-hydroxyquinoline) with special emphasis on compound ASS234, an N -propargylindole derivative. The description of the in vitro biological properties of the compounds and discussion of the corresponding structure-activity-relationships allows us to highlight new issues for the identification of more efficient MTDL for use in AD therapy.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

ASS234, As a New Multi-Target Directed Propargylamine for Alzheimer's Disease Therapy

  • Marco-Contelles, José
  • Unzeta López, Mercedes|||0000-0002-7113-3383
  • Bolea Tomás, Irene|||0000-0001-9591-980X
  • Esteban, Gerard|||0000-0002-9383-2150
  • Ramsay, Rona R.
  • Romero, Alejandro|||0000-0001-5483-4973
  • Martínez-Murillo, Ricard
  • Carreiras, M. Carmo
  • Ismaili, Lhassane
Highlights: The complex nature of Alzheimer's disease (AD) has prompted the design of Multi-Target-Directed Ligands (MTDL) able to bind to diverse biochemical targets involved in the progress and development of the disease. In this context, we have designed a number of MTD propargylamines (MTDP) showing antioxidant, anti-beta-amyloid, anti-inflammatory, as well as cholinesterase and monoamine oxidase (MAO) inhibition capacities. Here, we describe these properties in the MTDL ASS234, our lead-compound ready to enter in pre-clinical studies for AD, as a new multipotent, permeable cholinesterase/monoamine oxidase inhibitor, able to inhibit Aβ-aggregation, and possessing antioxidant and neuroprotective properties.